NDC Active Ingredient Lapatinib Ditosylate

Active Ingredient Information

What is Lapatinib Ditosylate?

A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2.

What is the usage for Lapatinib Ditosylate?

Lapatinib is used to treat a certain type of breast cancer (HER2-positive). It works by slowing or stopping the growth of cancer cells.

How many products in the NDC database contain Lapatinib Ditosylate?

The NDC database has 13 products with the active ingredient Lapatinib Ditosylate. The following table lists all the products that have this active ingredient.

NDC Products with Lapatinib Ditosylate

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0078-0671Proprietary Name: Tykerb LapatinibTabletOralNovartis Pharmaceuticals CorporationACTIVE
33656-0014Proprietary Name: Lapatinib Ditosylate MonohydratePowderChongqing Biocare Pharmaceutical Ltd.ACTIVE
48087-0095Proprietary Name: Lapatinib DitosylatePowderF.i.s. Fabbrica Italiana Sintetici S.p.a.ACTIVE
54245-7005Proprietary Name: Lapatinib DitosylatePowderScianda(changshu) Pharmaceuticals, Ltd.ACTIVE
54893-0110Proprietary Name: Lapatinib Ditosylate MonohydratePowderMsn Laboratories Private LimitedACTIVE
59116-4480Proprietary Name: Lapatinib DitosylatePowderCambrex Charles City, IncACTIVE
62207-980Proprietary Name: Lapatinib DitosylatePowderGranules India LimitedACTIVE
63850-7421Proprietary Name: Lapatinib Ditosylate AnhydrousPowderNatco Pharma LimitedACTIVE
66499-0046Proprietary Name: Lapatinib DitosylatePowderFormosa Laboratories, Inc.ACTIVE
68180-801Proprietary Name: Lapatinib LapatinibTabletOralLupin Pharmaceuticals, Inc.ACTIVE
68554-0072Proprietary Name: Lapatinib DitosylatePowderHetero Labs LimitedACTIVE
76361-0005Proprietary Name: Lapatinib DitosylatePowderBdr Lifesciences Private LimitedACTIVE
86184-222Proprietary Name: Lapatinib DitosylatePowderMaeda IncACTIVE
<